PF 6650808

Drug Profile

PF 6650808

Alternative Names: PF-06650808; PF-6650808

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action Notch-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Feb 2017 Pfizer suspends participant recruitment in a phase I trial in Solid tumours (Late-stage disease) in USA (IV)
  • 14 Apr 2016 Phase-I development is ongoing in USA
  • 31 Jul 2014 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top